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Abstract: The broad interdisciplinary nature of biocatalysis fosters innovation, as different technical
fields are interconnected and synergized. A way to depict that innovation is by conducting a survey on
patent activities. This paper analyses the intellectual property activities of the last five years (2014–2019)
with a specific focus on biocatalysis applied to asymmetric synthesis. Furthermore, to reflect the
inventive and innovative steps, only patents that were granted during that period are considered.
Patent searches using several keywords (e.g., enzyme names) have been conducted by using several
patent engine servers (e.g., Espacenet, SciFinder, Google Patents), with focus on granted patents
during the period 2014–2019. Around 200 granted patents have been identified, covering all enzyme
types. The inventive pattern focuses on the protection of novel protein sequences, as well as on
new substrates. In some other cases, combined processes, multi-step enzymatic reactions, as well
as process conditions are the innovative basis. Both industries and academic groups are active in
patenting. As a conclusion of this survey, we can assert that biocatalysis is increasingly recognized as
a useful tool for asymmetric synthesis and being considered as an innovative option to build IP and
protect synthetic routes.
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1. Motivation. The Role of Granted Patents as Key Actors in Innovation
Biocatalysis is currently recognized as a mature technology for asymmetric synthesis, based on
the excellent selectivity (enantio-, chemo, and regio-) that enzymes often display in many chemical
processes. The field has experienced a tremendous development when emerging Molecular Biology
techniques, used to produce and design enzymes, have been synergized with both process-development
concepts (batch to continuous reactors) and medium engineering strategies (non-aqueous media,
immobilization, etc.). As a result, biocatalysis can fulfil, in many cases, the demands of modern organic
synthesis, which must align a high selectivity and efficiency with sustainability and tight economic
figures. As a result, an increasing number of industrial processes have been successfully established,
comprising many diverse examples using free enzymes, whole cells, systems biocatalysis, multi-step
processes, etc. [1–19].
The abovementioned broad interdisciplinarity profile makes biocatalysis in a fertile landscape for
innovation. It is common that researchers of different backgrounds (chemistry, biology, engineering, etc.)
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cooperate closely in setting up new enzymatic reactors [20–23]. Overall, each biocatalytic industrial
reaction contains highly evolved parts, which are not standing alone, but that do form a robust
process when all of them are combined smartly. Some key concepts for industrial biocatalysis
may be: i) designed enzyme variants with improved selectivity, high resistance to chemicals,
thermostability, etc. [24–30]; ii) bio-based (non-conventional) solvents used as co-solvents in water,
or as biphasic systems [31–38]; neoteric solvents, such as deep eutectic solvents (DES) [39–44];
iii) whole-cells [45–48], immobilization [49–56], continuous processes, etc. [12,23,57,58]; and iv)
metrics [59–62], high productivities to assure an industrially-sound reaction.
To obtain deeper insights into these expected innovations, this paper discloses a patent survey
related to biocatalysis applied to asymmetric synthesis. Although this genre of studies is (surprisingly)
rather scarce in the open literature [8,63,64], we believe that the approach may nicely reflect the modern
trends in the field, provided by academic and industrial groups, and comprising different enzymes
and chemical processes. Importantly, to further refine the innovation assessment, the focus of the
study is put solely on those patents that have been granted over the last five years (2014–June 2019).
Remarkably, granted patents may provide further proofs on the necessary steps of novelty, innovation,
and resolution of industrial problems, as demanded for intellectual property (IP) rights. To simplify
the reading of the article, the granted patents are discussed by enzyme types, covering several relevant
case studies. Moreover, the focus of the article is strictly scientific, and no information regarding
the countries in which the invention is granted, nor whether or not patent fees are being satisfied,
is provided. It must be noted, however, that readers can easily retrieve that information from the patent
servers, by simply tracking the patent number provided in the references. To follow a consistency with
publication rules, the years denoted in the references are the publication years; in all cases, the effective
dates of those granted patents mentioned in this article are included between 2014–2019, and it can
be retrieved from patent servers as well. According to the survey, around 200 patents related to
biocatalysis have been successfully granted within the last five years, as shown in Figure 1.
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and the main strategies to achieve patentability are either the protection of known enzymes and 
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pharmaceutical and fine chemistry firms – several academic groups have proven to be active in IP 
activities as well. 
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several patent engine servers (e.g., Espacenet, SciFinder, Google Patents).
Notably, examples for all enzyme types have been found, for asymmetric synthesis purposes,
and the main strategies to achieve patentability are either the protection of known enzymes and
variants with different sequences (covering up to some homology), or the use of novel substrates
for the intended reactions, or a combination of both approaches. Apart from industrial activities –
pharmaceutical and fine chemistry firms – several aca e ic groups have proven to be active in IP
activities a well.
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2. Granted Patents Related to Hydrolases in Asymmetric Synthesis
2.1. Lipases
Hydrolases (Enzyme Commission number EC 3,) undeniably represent the most valuable type of
enzymes in applied biocatalysis, due to their unique properties, such as broad substrate specificity,
commercial availability, lack of need to use any cofactor, and high capability to work at high substrate
concentrations [65–73]. Inside this group of enzymes, lipases (EC 3.1.1.3) can be considered the
most useful, according to the ample number of processes in which they have been employed at
lab [74–77] and industrial scale [78–82], mainly because they can perform with notable precision
(chemo-, regio- and/or stereoselectivity) not only in their natural environment (aqueous solutions) but
also in non-conventional media [66,75,79,82–85], therefore being catalogued as natural promiscuous
enzymes [86]. Although the main industrial uses of lipases are in the detergent and food and beverage
areas, there are plenty of examples in which these enzymes are employed in asymmetric synthesis [63];
in this sense, examples taken from granted patents in the last five years are hereunder presented.
2.1.1. Stereoselective Hydrolysis Catalyzed by Lipases
Thus, regarding the employ of lipases in the preparation of chiral building blocks for the synthesis
of active pharmaceutical ingredients (APIs), some recent patents describe different stereoselective
hydrolytic procedures taking advantage of the enzymatic capability of discriminating between
enantiomers. For instance, a patent from Zhejiang Changming Pharmaceutical Co., Ltd., [87],
granted in 2018, describes the preparation of the anti-epileptic drug levetiracetam (Keppra®, Elepsia®)
starting from racemic methyl 2-bromo(chloro)butanoate, using Novozym 435, a commercially available
preparation of lipase B from Candida antarctica immobilized on Lewatit VP OC 1600, a macroporous
acrylic polymer resin [88]. The key step, a kinetic resolution of a racemic 2-haloester 1, leads to
the (S)-acid and the desired ester (R)-2, which is extracted using ethyl acetate and converted into
levetiracetam via transformation of the (R)-ester into the α-aminoamide (S)-3 and a further cyclization
with 4-chlorobutanoyl chloride, as shown in Scheme 1.
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Scheme 1. Chemoenzymatic preparation of levetiracetam starting from a racemic 2-haloester.
In another example, developed by Daiichi Sankyo Co. Ltd., and granted in 2019 [89], the kinetic
resolution of (R,S)-1-((((1,1,1,3,3,3-hexafluoropropan-2-yl)oxy)carbonyl)oxy)ethyl isobutyrate ((R,S)-4)
was carried out by a lipase-catalyzed hydrolysis in a buffer/organic solvent biphasic system to discard
the corresponding alcohol (S)-5 from the desired ester (R)-4 (Scheme 2).
In order to catalyze this enzymatic hydrolysis, different commercial lipases (from C. antarctica,
Candida rugosa and Thermomyces lanuginosus), organic cosolvents (acetonitrile, ethers, saturated and
aromatic hydrocarbons, alcohols) and reaction conditions (temperature from 0 ◦C to 80 ◦C, reaction
times ranging from 1 h to 120 h) were tested; the best results were obtained with Chirazyme L2,
C4 (a commercial preparation of C. antarctica lipase similar to Novozym 435) and buffer pH=7/MTBE
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(5/1, V/V) at 20 ◦C, with reported conversions of around 40% and ee values higher than 99%.
Subsequently, (R)-4 was used to furnish a carbamate 7 upon reaction with the enantiopure amide 6
(as a sulphonic salt). This carbamate 7 is a promising prodrug useful as inhibitor of carboxypeptidase U
(also known as activated thrombin-activatable fibrinolysis inhibitor, TAFIa), for treating thromboembolic
disorders [90–92].Catalysts 2019, 9, x FOR PEER REVIEW 4 of 41 
 
 
Scheme 2. Synthesis of prodrug 7 possessing TAFIa inhibitory activity. 
In order to catalyze this enzymatic hydrolysis, different commercial lipases (from C. antarctica, 
Candida rugosa and Thermomyces lanuginosus), organic cosolvents (acetonitrile, ethers, saturated and 
aromatic hydrocarbons, alcohols) and reaction conditions (temperature from 0 °C to 80 °C, reaction 
times ranging from 1 h to 120 h) were tested; the best results were obtained with Chirazyme L2, C4 
(a commercial preparation of C. antarctica lipase similar to Novozym 435) and buffer pH=7/MTBE 
(5/1, V/V) at 20 °C, with reported conversions of around 40% and ee values higher than 99%. 
Subsequently, (R)-4 was used to furnish a carbamate 7 upon reaction with the enantiopure amide 6 
(as a sulphonic salt). This carbamate 7 is a promising prodrug useful as inhibitor of carboxypeptidase 
U (also known as activated thrombin-activatable fibrinolysis inhibitor, TAFIa), for treating 
thromboembolic disorders [90–92]. 
Another enzymatic hydrolysis useful for synthesizing drug precursors was patented by Beijing 
University of Chemical Technology [93] and granted in 2017; the stereoselective hydrolysis of a 
racemic mixture of N-protected cis-4-amino-cyclopent-2-en-1-ol (cis-8, 20 g/L, Scheme 3) was carried 
out using lipase B from C. antarctica at pH=5 and 60 °C in 4h, to furnish the desired alcohol (1S,4R)-9 
(conversion 45%, ee 99%). This enantiopure alcohol is a building block for the preparation of 
ticagrelor (Brilinta®, Brilique®, Possia®) a platelet aggregation inhibitor originally produced by 
AstraZeneca [94,95]. 
A very interesting process, patented by and recently granted in 2019 to AbbVie Inc. describes 
preparation of an intermediate ((1R, 2R)-12, Scheme 4) in the synthesis of viral protease inhibitors 
[96]. In this case, a double enzymatic procedure is followed starting from (±)-dipropyl 2-
(difluoromethyl)cyclopropane-1,1-dicarboxylate (±)-10, and employing primarily a lipase (from T. 
lanuginosus or Rhizomucor miehei) in a biphasic medium (phosphate buffer with 10% DMF, 30 °C, 95 
h) to separate the undesired monoacid (1R, 2S)-11 (extracted from the reaction media using MTBE) 
from the chiral diester (R)-10 (64.4% yield, 97.4% ee). In a second step, an esterase from Bacillus subtilis 
cloned and expressed in cells from Escherichia coli was employed for the desymmetrization of the 
stereocentre at C1 of (R)-10 to yield (1S, 2R)-10 (84.2% yield, 99.4% ee) in an aqueous solution at 30 
°C in 68 h. 
Sche e 2. Synthesis of prodrug 7 possessing FIa inhibitory activity.
Another enzymatic hydrolysis useful for synthesizing drug precursors was patented by Beijing
University of Chemical Technology [93] and granted in 2017; the stereoselective hydrolysis of a racemic
mixture of N-protected cis-4-amino-cyclopent-2-en-1-ol (cis-8, 20 g/L, Scheme 3) was carried out using
lipase B from C. antarctica at pH = 5 and 60 ◦C in 4 h, to furnish the desired alcohol (1S,4R)-9 (conversion
45%, ee 99%). This enantiopure alcohol is a building block for the preparation of ticagrelor (Brilinta®,
Brilique®, Possia®) a platelet aggregation inhibitor originally produced by AstraZeneca [94,95].Catalysts 2019, 9, x FOR PEER REVIEW 5 of 41 
 
 
Scheme 3. Synthesis of an enantiopur  precursor of ticagrelor. 
 
Scheme 4. Chemoenzymatic synthesis of an enantiopure precursor of a viral protease inhibitor. 
All the patents mentioned up to this point share the common feature of placing the enzymatic 
asymmetric hydrolysis in an initial stage of the synthetic scheme leading to the desired API. More 
infrequently, the enzymatic biotransformation is applied once the structure of the API is almost 
complete. For instance, a patent from Tiantai Yisheng Biochemical Technology Co., Ltd., (granted in 
2019) describes the enantioselective hydrolysis of racemic esters of valsartan (Diovan®, an 
angiotensin II receptor blocker (ARBs or sartans), a drug which modulates the renin–angiotensin 
system, used in the treatment of hypertension, diabetic nephropathy and congestive heart failure 
[97]) catalyzed by lipases [98], as depicted in Scheme 5.  
Scheme 3. Synthesis of an enantiopure precursor of ticagrelor.
Catalysts 2019, 9, 802 5 of 42
A very interesting process, patented by and recently granted in 2019 to AbbVie Inc.
describes preparation of an intermediate ((1R, 2R)-12, Scheme 4) in the synthesis of viral
protease inhibitors [96]. In this case, a double enzymatic procedure is followed starting from
(±)-dipropyl 2-(difluoromethyl)cyclopropane-1,1-dicarboxylate (±)-10, and employing primarily a
lipase (from T. lanuginosus or Rhizomucor miehei) in a biphasic medium (phosphate buffer with 10% DMF,
30 ◦C, 95 h) to separate the undesired monoacid (1R, 2S)-11 (extracted from the reaction media using
MTBE) from the chiral diester (R)-10 (64.4% yield, 97.4% ee). In a second step, an esterase from Bacillus
subtilis cloned and expressed in cells from Escherichia coli was employed for the desymmetrization of
the stereocentre at C1 of (R)-10 to yield (1S, 2R)-10 (84.2% yield, 99.4% ee) in an aqueous solution at
30 ◦C in 68 h.
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Scheme 4. Chemoenzymatic synthesis of an enantiopure precursor of a viral protease inhibitor.
All the patents mentioned up to this point share the common feature of placing the enzymatic
asymmetric hydrolysis in an initial stage of the synthetic scheme leading to the desired API. More
infrequently, the enzymatic biotransformation is applied once the structure of the API is almost
complete. For instance, a patent from Tiantai Yisheng Biochemical Technology Co., Ltd., (granted in
2019) describes the enantioselective hydrolysis of racemic esters of valsartan (Diovan®, an angiotensin
II receptor blocker (ARBs or sartans), a drug which modulates the renin–angiotensin system, used in
the treatment of hypertension, diabetic nephropathy and congestive heart failure [97]) catalyzed by
lipases [98], as depicted in Scheme 5.
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Thus, different commercial immobilized lipases (Lipozyme TL IM (T. lanuginosus), Lipozyme RM
IM (R. miehei), Novozym 435 (lipase B from C. antarctica) from Novozymes; lipases PS IM (Burkholderia
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cepacia), Lipase AK (Pseudomonas fluorescens) and Lipase AS (Aspergillus niger), from Amano) were
used for the hydrolysis of racemic esters ((R,S)-13, R = ethyl, methyl or isopropyl) in a buffer solution
(pH varying between 4.0–9.0) with different amounts of organic cosolvents (acetone, isopropanol or
ethyl acetate), rendering the desired valsartan ((S) absolute configuration) in good yields (up to 90–95%
after work-up) and enantiopurity (up to 99.5%).
2.1.2. Regio- and Chemoselective Hydrolysis Catalyzed by Lipases
Lipases can be also used for the regioselective hydrolysis of a specific ester group without
altering another similar functional groups placed in another part of the molecule, under very mild
reaction conditions. In a recent patent from Harbin University of Commerce, granted in 2019 [99],
a lipase (from Candida sp. among others) catalyzing the monohydrolysis of nifedipine (dimethyl
2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate (Scheme 6), a calcium channel
blocker [100]) is reported to furnish the corresponding monoacid 14; this reaction is carried out in a
mixed system of aq. soln./org. solvent (such as isooctane, hexane, cyclohexane or toluene), and reacting
under stirring at 30–40 ◦C for 3–5 days. The monoacid (23% yield, no ee reported) is the key step for
synthesizing other 1,4-dihydropyridine structures possessing two different alkoxycarbonyl groups in
positions 3 and 5 (such as aranidipine, azeldinipide, barnidipine, etc.), which are more selective and
efficient drugs [101].
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results) and esterases for the hydrolysis of different alkyl esters of N-Boc-(1R,3S,4S)-2-
azabicyclo[2.2.1]heptane-3-carboxylate (16, Scheme 7), to yield acid 17 without removing the 
carbamate protecting group. In this process, essential for the preparation of ledispavir (Harvoni®, 
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The possibility of performing chemoselective reactions is another attractive property of
lipases. In this sense, a patent from AstaTech Chengdu Biopharmaceutical Co., Ltd. granted
in 2018 [102], reports the use of several lipases (Novozym 435 and lipase from pig pancreas
leading to the best results) and esterases for the hydrolysis of different alkyl esters of
N-Boc-(1R,3S,4S)-2-azabicyclo[2.2.1]heptane-3-carboxylate (16, Scheme 7), to yield acid 17 without
removing the carbamate protecting group. In this process, essential for the preparation of ledispavir
(Harvoni®, Gilead, in combination with sofosbuvir (see Scheme 14) for treatment of hepatitis C [103],
the enzymatic hydrolysis allows the preparation of 17 in good yields (up to 77%) and high d.e. values
(up to 99.7%), therefore avoiding the main problem of the chemical basic hydrolysis (LiOH in THF/H2O),
a partial racemization of the stereogenic center at Cα of the alkoxycarbonyl group.
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2.1.3. Stereoselective Acyl-Transfer Catalyzed by Lipases
As stated above [66,75,79,82–85], lipases are perfectly capable of working in non-aqueous reaction
media, therefore catalyzing acyl transfer processes (esterifications, transesterifications, amidations,
etc) with excellent precision. Hence, in a patent from Ningbo Xinkai Biotechnology Co., Ltd.,
granted in 2017 [104], the use of Nozozym 435 for the stereoselective monoacylation of prochiral
2-(2-(2,4-difluorophenyl)allyl)propane-1,3-diol 18 (Scheme 8) with isopropanoic anhydride in a mixture
of NaHCO3/toluene at 15 ◦C during 24 h is reported to furnish monoester 19 (75% yield, ee not
reported), a chiral building block for the preparation of antifungic posaconazole (Noxafil®, Posanol®).
This biocatalytic monoacylation is not the real innovation of the patent, because it was described
previously for this same enzyme using vinyl acetate in acetonitrile [105]; in this case, the synthesis of
starting diol 18 is claimed to improve the previously reported procedures [106–108].
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The use of biotransformations in the synthesis of statins, inhibitors of 3-hydroxy-3-methylglutaryl
coenzyme A (HMG-CoA) reductase, widely prescribed for the pharmacological treatment of
hypercholesterolemia and dyslipidaemia, has been recently reviewed [109,110] In this context, we will
comment some recently granted patents using different enzymes.
For instance, Shandong Qidu Pharmaceutical Co., Ltd. patented a transesterification protocol,
granted in 2016 [111] and schematized in Scheme 9 for the preparation of pitavastatin (Livalo®,
Livazo®, among others trade names), a member of the superstatin family [109].
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Scheme 9. Preparation of Pitavastatin through an enzymatic transesterification.
In this process, the biocatalyst (commercial lipases from different origins, the best results being
obtained with lipase from B. cepacia) is able to discriminate between the stereoisomers of starting
diol 20 (it is not specified in the patent if 20 is a mixture of the four possible stereoisomers, although
according to the reported results it must be a racemic mixture of syn enantiomers). The acylation is
carried out in a biphasic medium phosphate buffer/organic solvent (dichloromethane, ethyl acetate,
tetrahydrofuran, methyl tert-butyl ether, cyclohexane, toluene or xylene) in different ratios (from 12 to
1/5, V/V) at temperatures ranging from 0 to 40 ◦C, and different reaction times (up to 72 h). Reaction
yields varied between 43.1 and 47.3%, with excellent enantiopurity of the diacetate (3R, 5S)-21 (97–99%),
which is separated (by ethanol precipitation) from the non-converted diol (3S, 5R)-20, and subsequently
hydrolyzed chemically (EtOH/NaOH) and stirred with a CaCl2 solution to finally furnish the calcium
salt of pitavastatin.
Treprostinil (Remodulin®, Orenitram®, Tyvaso®, Scheme 10), a synthetic analog of prostacyclin
(PGI2), is a vasodilator used for the treatment of pulmonary arterial hypertension [112], of which
synthesis is complex and time consuming [113]. In a patent from Everlight Chemical Industrial
Corporation granted in 2016, a stereo- and regioselective acylation of diol 21 with vinyl acetate,
performed in n-hexane at 22 ◦C with lipase AK from Amano, leads to the regioselective acylation of
the hydroxyl group in the cyclic moiety of 21 without acylating the one on the exocyclic chain, and
leading to the desired stereochemistry of 22 (no yields or ee reported).
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In another patent from Wuxi Fortune Pharmaceutical Co., Ltd., granted in 2018 [114], the gram-scale
kinetic resolution (Scheme 11) of racemic hidroxynitrile (R,S)-24, obtained from racemic epyclorhydrine
(R,S)-23, was reported using an enzymatic transesterification with perchlorophenyl acetate and lipase B
from C. antarctica, supported on an acid resin (Novozym 435?), to obtain acetate (R)-25, which hydrolysis
leads to L-carnitine, an essential co-factor in the metabolism of lipids involved in the generation of
cellular energy [115,116].
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Scheme 11. Chemoenzymatic preparation of L-carnitine.
The resolution of chiral amines is a very attractive research area, because of the plethora of
applications described for such enantiopure compounds [117,118], which can be obtained by using
oxidoreductases [119] (see Section 3.2), transaminases [120] (Section 4), and lipases [121,122], as we
will comment here. In fact, different companies have been actively working in this area during the
last years. For instance, in patent granted in 2018 [123], a methodology for preparing enantiopure
(R)-1,2,3,4-tetrahydronaphthalen-2-amine (2-aminotetralin, 2-AT, (R)-27, Scheme 12a), a rigid analogue
of phenylisobutylamine capable to inhibit the reuptake of serotonin and norepinephrine [124] was
reported. In this case, the reaction was carried out in a 2 L autoclave filled with 1 L of toluene, 117.6 g
of (R,S)-27 (obtained via reductive amination of starting ketone 26), 172 g of (R)-O-acetyl mandelic acid,
commercial Novozym 435 and H2/nickel catalyst (KT-02) to transform the kinetic resolution into a
dynamic kinetic resolution by racemizing the unreacted (S)-27. After 24 h, 144.2 g of (R)-28 (95% yield,
99% ee) were isolated and subsequently hydrolyzed to finally yield (R)-28 with excellent yield (92%)
and enantiopurity (99%).
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In another very similar example shown in Scheme 12b, the dynamic kinetic resolution of (R,S)-29
was reported in a patent [125] granted in 2018 for the preparation of an enantiopure intermediate in the
synthesis of rasagline (Azilect®), an irreversible inhibitor of monoamine oxidase-B, used as a single
therapy in the symptomatic treatment in early stages of Parkinson’s disease or as an additional therapy
in more severe cases [126,127]. In this case, the lipase used is different, but the final results (0.5 L
reaction volume) are also excellent in terms of both yield and enantiopurity. Finally, the preparation
of optically pure (R)-1-phenylethan-1-amine ((R)-31, Scheme 12c) is described following a similar
methodology in another patent [128] granted in 2017.
2.1.4. Site-selective Acyl-Transfer Catalyzed by Lipases
The lipase capability for catalyzing site-selective acylations/deacylations has been also exploited
in recently granted patents. For instance, a HC-Pharma AG patent granted in 2018 [129] describes the
mono-deacetylation of 33 (Scheme 13), a precursor in the preparation of sofosbuvir (Sovaldi®, Gilead),
a direct acting antiviral medication used as part of combination therapy to treat chronic hepatitis
C [130].
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Scheme 13. Chemoenzymatic synthesis of sofosbuvir.
The deacetylation is carried out using 500 g of 33 in 5 L of an alcoholic medium (isopropanol,
methoxypropanol or ethanol/water) via a single transesterification at 60◦ during 48 h of the acetoxy
group at position 5’ using 100 g of a resin-supported lipase B from C. antarctica (Novozym 435?) as the
catalyst, leading to quantitative yields (between 99.2 and 99.6%) after a simple purification procedure
(cooling to 25 ◦C, filtering out the lipase, solvent distillation to a residual volume of 900 mL and
precipitation at 0 ◦C).
The site-selective monoacylation of the sugar moiety of useful glycosides has been also
patented. For instance, acylation of polydatin (3,4,5-trihydroxystilbene-3-β-D-glucopyranoside),
a pharmacological compound isolated from the root and rhizome of the traditional Chinese medicinal
plant Polygonum cuspidatum, widely applied in anti-inflammatory, anti-oxidant and in anti-angiogenesis
chemotherapy [131,132], has been reported in a patent from Huaiyin Institute of Technology, granted in
2018 [133]. This process, depicted in Scheme 14a, uses immobilized lipase from C. antarctica (Novozym
435?), amongst others, in 2-MeTHF, a biogenic solvent considered a renewable alternative to THF and
other organic solvents [33,134], to furnish almost quantitative yields of 36, the monoacyl derivative at
the OH group at C6 of the glucopyranoside moiety, a useful prodrug of polydatin.
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eniposide is an important component of Gardenia jasminoides Ellis, a plant from Yinchenhao Tang,
useful in the prevention and therapy of hepatic injury (HI) [135]. The site-selective monoacylation
of geniposide (Scheme 14b) to furnish the more active and stable C-6′-lauroyl monoester has been
reported in a patent from Nanjing Tech University, granted in 2019 [136], using different lipases (Rh.
miehei, lipases A and B from C. Antarctica (Novozym 435?)) adsorbed on silica gel (easily separated by
filtering after reaction) in THF at 45 ◦C (yields up to 78%).
In another example, the monoacetylation of (Z)-5-ethylidene-8-hydroxy-7-((3-hydroxypyridin-4-yl)
methyl)-3,4,5,6,7,8-hexahydro-1H-pyrano[3,4-c]pyridin-1-one (38, Scheme 15), derived fro the
iridiod-type aglycon of ulti-active s ertia arine [137–139], is reported in a patent fro Jiangxi
Science & Technology Normal University granted in 2018 [140]. In this patent, compound 38 is obtained
by a controlled fermentation of Swertia mussoti dry roots using cells from Aspergillus niger, isolated and
acylated with vinyl acetate and Novozym 435 to provide 39 (acylated only in the aromatic OH group,
no yield reported), an alkaloid which anti-hepatitis and anticancer activity seems to be very promising.
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of lipases for hydrolysis [141,142] or acylations [143–147] taking advantage of the very mild reaction
conditions in which they were carried out. Particularly interesting are those granted patents reporting
the opening of δ-valerolactone and ε-caprolactone with mercapto-alcohols catalyzed by Novozym
435 for the preparation of polymers [148], or the lipase-catalyzed preparation of enantiopure (R) and
(S)-leucine [149]. On the other hand, the in-situ reaction of vinyl acetate with isopropanol in the
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a previously described strategy [150]) is used in a Biginelli reaction with a β-dicarbonyl compound,
urea and water to produce different 3,4-dihydro-pyrimidin-2(1H)-ones, useful for the preparation of
dark blue solid fluorescent materials [151].
To finish this section, we will illustrate an example of the well-known lipase
promiscuity [68,86,152,153]. Thus, in a patent from Nanjing Tech University granted in 2018 [154],
different lipases (lipase from pig pancreas (PPL) leading to the best results) were used for catalyzing the
Knoevenagel condensation between indolin-2-one (Scheme 16, 40) and different aromatic aldehydes 41
to synthesize the corresponding 3-arylidene derivatives 42, useful in the synthesis of indole alkaloids
with many therapeutic activities (antibacterial, antitumor or anti-inflammatory). Different reaction
conditions were tested (solvent, temperature, etc.), being the best results obtained with a mixture of
water/DMSO (1/4, v/v) and 45 ◦C.
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Using nitrilases, other patents cover the asymmetric synthesis of β-alanine from β-
aminopropionitrile at high substrate loadings (> 200 g L−1) [168], an improved process for the 
production of pregabalin (see scheme 34, below), the active agent in Lyrica®, a drug employed in the 
treatment of epilepsy, neuropathic pain and fibromyalgia [169,170] starting from dinitrile substrates 
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2.2. Other Hydrolases
Apart from lipases (see the previous section), other types of hydrolases have been subject of
IP protection as well. For instance, novel specific sequences of esterases have been patented and
successfully employed in the kinetic resolution of esters of mandelic acid [155], phenyl ethanol [156],
lactate derivatives [157], or cocaine [158], as well as for the synthesis of vetiveryl esters [147].
Moreover, some esterases have been used in the penicillin production area, like in the synthesis of
3-deacetyl-7-aminocephalosporaic acid [159].
Likewise, nitrilases have been extensively characterized and protected over the last five years.
Companies like BASF [160–163] and c-LEcta [164] have patented novel sequences of nitrilases, with
potential use in biocatalysis in asymmetric synthesis. In addition, some other activities cover sequences
applied to specific targets for pharmaceuticals and fine chemicals. For instance, nitrilases are used to
generate chirality in the synthesis of precursors of L-praziquantel, a drug employed against parasitic
worm infections [165,166]. Nitrilases from Arabidopsis thaliana, Aspergillus niger or Alcaligenes faecalis are
claimed in a patent granted in 2014 from Suzhou Tongli Biomedicine Co., Ltd., to perform the kinetic
resolution of nitrile 43 (Scheme 17) [167] to obtain the enantiopure (R)-43, needed for the synthesis of
the required drug.
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Using nitrilases, other patents cover the asymmetric synthesis of β-alanine from
β-aminopropionitrile at high substrate loadings (> 200 g L−1) [168], an improved process for the
production of pregabalin (see Scheme 34, below), the active agent in Lyrica®, a drug employed in the
treatment of epilepsy, neuropathic pain and fibromyalgia [169,170] starting from dinitrile substrates
(developed by Hikal Ltd) [171,172], or the production of 1-cyancyclohexylacetic acid by means of
engineered nitrilases, and starting from the dinitrile substrate as well [173]. In another example,
the synthesis of (R)-46, a precursor of ivabradine (Corlanor®, Procoralan®, Coralan®, Corlentor®,
Lancora® or Coraxan®, a drug prescribed for the symptomatic management of stable heart-related
chest pain and heart failure [174,175]) has been developed and patented by Servier [176] (granted in
2015), using a nitrilase to generate the chirality through hydrolysis of the racemic nitrile (R,S)-45 to
furnish the carboxylic acid (R)-46, as depicted in Scheme 18.
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Likewise, nitrilases have been used in the asymmetric synthesis of the statin side-chain,
by hydrolysing the nitrile group [177–179]. The combination of nitrilases with halohydrin dehalogenases
enables a continuous process for the efficient production of that important building block with high
productivities and selectivities [179]. As reported in Section 2.1.3, the statin field is one of the most active
ones when biocatalysis applied to IP generation is concerned. Other examples involving nitrilases cover
the synthesis of pharmaceutical drugs like fosamprenavir [180], as well as clopidogrel [181]. Apart from
nitrilases, penicillin G acylases have been used for the synthesis of optically active phenylglycine
derivatives (through kinetic resolution strategies) [182].
3. Granted Patents Related to Oxidoreductases in Asymmetric Synthesis
3.1. Ketone Reductions
Alcohol dehydrogenases (ADHs; E.C. 1.1.1.x), also called ketoreductases (KREDs) or carbonyl
reductases (CRs), are oxidoreductases that selectively catalyze the reversible conversion of carbonyl
compounds into the corresponding alcohols, requiring the presence of nicotinamide cofactors (NADH or
NADPH) to perform their activity. During the course of the reduction, the enzyme delivers a
hydride from the cofactor C4 to the Si- (anti-Prelog ADHs) or to the Re-face (Prelog enzymes) of
the carbonyl compound, yielding (R)- or (S)-alcohols, respectively [183–187]. Efficient cofactor
regeneration methodologies are required due to the high costs of nicotinamides and inhibition
processes. Thus, the biocatalyzed reduction is coupled with a secondary reaction to regenerate the
nicotinamide cofactors [188–190]. In general, a second enzymatic reaction is employed, for example by
combining glucose with glucose dehydrogenase (GDH), glucose-6-phosphate with glucose-6-phosphate
dehydrogenase (G6PDH) or sodium formate with formate dehydrogenase (FDH). NAD(P)H can also
be regenerated by using a coupled substrate approach, in which the ADH catalysed the desired
bioreduction and the oxidation of a cosubstrate, in general isopropanol (IPA), which is oxidized to
acetone. Ketone reduction is under thermodynamic control, so that a large excess of IPA is required.
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Over the last five years, several procedures describing the use of KREDs for the preparation of valuable
compounds have been patented.
Thus, a patent granted to Codexis Inc. described the preparation of ezetimibe (Zetia®,
Ezetrol®, amongst other), a drug employed to treat high blood cholesterol and other lipids
abnormalities [191–193], using different engineered KREDs from Lactobacillus brevis, Lactobacillus
kefir and Lactobacillus minor in a patent granted in 2014 [194]. The ezetimibe precursor
5-((4S)-2-oxo-4-phenyl-(1,3-oxazolidin-3-yl))-1-(4-fluorophenyl)pentane-1,5-dione (47) was selectively
reduced to (4S)-3-[(5S)-5-(4-fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1,3-oxazolidin-2-one (48),
as depicted in Scheme 19a, with complete selectivity and conversions higher than 95% after 24
h. Glucose and glucose dehydrogenase (GHD) were employed as secondary enzymatic system to
regenerate the NADP+ consumed during the bioreduction. Substrate concentrations were at least of
100 g/L whereas 5 g/L of biocatalyst can be employed.
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fluoroaniline and toluene as solvent (Scheme 19c). Immobilized KREDs have been also employed for 
the preparation of an ezetimibe precursor, as reported in a patent granted in 2018 [197]. Different 
techniques were applied to immobilize the biocatalyst, including adsorption, covalent binding, 
entrapping or cross-linked microencapsulated. Chiral alcohol was obtained with complete 
conversion after 18 hours, using IPA or the glucose/GDH system for the nicotinamide cofactor 
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The preparation of ezetimibe and some of its derivatives was also described in a further patent, also
by Codexis Inc., granted in 2015 [195]. Bioreduction of 1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3
-oxopropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone (49, Scheme 19b) was carried out by an engineered
KRED from Lactobacillus kefir, which sequence is given. Ezetimibe was obtained with excellent
diastereomeric excess (>99%) and high conversion (90%) after 24 h, being possible to use 50 g/L of
substrate. Different NAD(P)+ regeneration systems were employed, including a set of secondary
enzymatic systems with dehydrogenases and the use of the coupled-substrate approach in presence of
IPA. Ezetimibe synthesis was also described through a chemoenzymatic route in a patent granted in
2018 [196], shown in Scheme 19c. The reduction of different O-protected β-ketoesters 50 was carried
out in presence of a recombinant ketoreductase leading to the β-hydroxy-esters (S)-51 with high
optical purities (>95%) and yields higher than 90% after 24 h. Both IPA as cosubstrate or glucose/GDH
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as secondary enzymatic system were employed for the cofactor regeneration system. The chiral
β-hydroxyesters were employed to prepare an Ezetimibe intermediate (S)-52 by bromination with
different brominating reagents in presence of p-fluoroaniline and toluene as solvent (Scheme 19c).
Immobilized KREDs have been also employed for the preparation of an ezetimibe precursor, as reported
in a patent granted in 2018 [197]. Different techniques were applied to immobilize the biocatalyst,
including adsorption, covalent binding, entrapping or cross-linked microencapsulated. Chiral alcohol
was obtained with complete conversion after 18 h, using IPA or the glucose/GDH system for the
nicotinamide cofactor regeneration.
The efficacy of statins, inhibitors of the 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA)
reductase, against all the forms of hypercholesterolemia and for the prevention of cardiovascular
events [110] has been already mentioned in Section 2.1.3. In the last years, some patents employing
ketoreductases have been published for the preparation of these compounds. Thus, in 2016 a
patent was granted [198] describing the use of an engineered bacterium for the preparation of
(3R,5S)-6-chloro-3,5-dihydroxyhexanoic acid tert-butyl ester (3R,5S)-55, a chiral precursor of statins.
The engineered bacteria contained an ADH gene from Lactobacillus kefir DSM20587 (ADHR), a carbonyl
reductase gene and a glucose dehydrogenase gene for the nicotinamide cofactor regeneration
(Scheme 20a). The bacterial resting cells were employed in the bioreduction of 6-chloro-3,5-carbonyl
hexanoate (53) in the presence of glucose and isopropanol in order to obtain the chiral diol (3R,5S)-55
with complete selectivity and high yields in a two-step procedure. In 2017, another patent was
granted reporting the preparation of a set of statins using a chemoenzymatic methodology [199].
Thus, KRED-130, commercially available from Codexis, was able to reduce the keto group of the
intermediate 56 to the corresponding chiral alcohol (R)-57 with quantitative yield and optical purities
higher than 99.5% (Scheme 20b). A year later, a set of diketones intermediates in the preparation of
statins were selectively reduced by different KREDs to the corresponding chiral 1,3-diols in a process
carried out in buffer containing some organic solvents as ethanol, acetonitrile, toluene or hexane,
among others [200]. Depending on the substrate structure, the chiral diols were obtained with yields
around 90% and excellent optical purities after 24 h.
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203]. In 2015, a patent describing the preparation of a montelukast sodium intermediate was granted 
[204]. The key step of this synthesis was the selective bioreduction of compound 58 (scheme 22) 
catalyzed by an alcohol dehydrogenase in buffer containing an organic solvent as hexane or toluene. 
IPA was employed as cosubstrate in order to regenerate the NAD+ cofactor. After 72 h, the chiral 
alcohol (S)-59 can be recovered with high yield and selectivity, and converted to the desired 
intermediate (S)-60 by treatment with methylmagnesium halide, as shown in Scheme 21. A year later, 
in a patent granted to Zhangjiagang Xinyi Chemical Co., a set of KREDs from Suzhou-Enzyme 
Biological Technology Co. were also employed in the bioreduction of the montelukast intermediate 
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Scheme 20. Synthesis of statin intermediates employing ketoreductases.
Montelukast (Airon®, Everest®, Singulair®, Sansibast®, Senovital®, Accord®, amongst others) is
an efficient and low toxicity anti-inflammatory, anti-allergy and asthma treatment compound [201–203].
In 2015, a patent describing the preparation of a montelukast sodium intermediate was granted [204].
The key step of this synthesis was the selective bioreduction of compound 58 (Scheme 22) catalyzed
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by an alcohol dehydrogenase in buffer containing an organic solvent as hexane or toluene. IPA was
employed as cosubstrate in order to regenerate the NAD+ cofactor. After 72 h, the chiral alcohol (S)-59
can be recovered with high yield and selectivity, and converted to the desired intermediate (S)-60 by
treatment with methylmagnesium halide, as shown in Scheme 21. A year later, in a patent granted to
Zhangjiagang Xinyi Chemical Co., a set of KREDs from Suzhou-Enzyme Biological Technology Co.
were also employed in the bioreduction of the montelukast intermediate 58 to yield optically active
alcohol (S)-59 [205]. Bioreductions were carried out in buffer containing toluene as cosolvent using
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Scheme 21. Preparation of montelukast intermediates employing KREDs under mild reaction conditions.
The biocatalytic conversion of oxcarbazepine 61 and analogues to chiral (S)-eslicarbazepine (S)-62
(a drug employed in the treatment of epilepsy [206]) and corresponding chiral alcohols is reported
in a patent granted in 2015 [207] using engineered ketoreductases from Lactobacillus, as shown in
Scheme 22. These biocatalysts were able to selectively reduce the starting ketones with optical purities
and conversions higher than 90% after 24 h, depending on the substrate structure.
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Scheme 22. Synthesis of (S)-eslicarbazepine (S)-62 employing KREDs.
A patent covering a multistep synthesis of a set of β-3-antagonists [208] with a pyrrolidine core
65 [209] (Scheme 23) has been granted in 2017 to Merck Sharp & Dohme Corp. [210]. One of these
steps comprises the use of four engineered KREDs, whose sequence is given, for the bioreduction of a
set of α-aminoketones 63 to the corresponding β-aminoalcohols 64 in a dynamic kinetic resolution
(Scheme 23) [211], leading to the stereoselective preparation of one of the diastereomers of the final
alcohol with excellent yields and optical purities. Reactions were performed in presence of several
cosolvents, whereas different enzymatic systems were tested for the nicotinamide cofactor recycling.
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Scheme 23. KREDs employed in the synthesis of different β-aminoalcohol intermediates of
β-3-antagonists.
Dehydroepiandrosterone (DHEA, 66) is a key intermediate in the synthesis of steroidal
molecules [212]. In 2018, a granted patent included a novel approach for preparing this valuable
compound by carrying out the bioreduction of the 3-oxo group of the 5∆-androstene-3,17-dione 65 in
presence of KREDs obtained from Sphingomonas wittichii [213]. DHEA could be obtained with yields
around 80–90% and selectivities higher than 90%, being only observed the reduction of the 3-oxo group,
when working at substrate concentrations of 50–300 g/L (Scheme 24). Some organic solvents immiscible
with water can be employed in the bioreductions in concentrations around 25–75%, and different
secondary enzymatic systems were used to regenerate the NAD(P)+ cofactor. The biocatalytic synthesis
of DHEA has been also described in a patent granted in 2019 [214] by carrying out the same reduction
at the 3-oxo positon of 65 in presence of an engineered KRED. The process was developed employing
the KRED as a powder and using GDH from Bacillus subtilis and glucose for the NADP+ recycling
or using whole cells containing both enzymes. Substrate can be employed at concentrations around
120–600 g/L, furnishing enantiopure DHEA with high yields.
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in the synthesis of duloxetine, was carried out with high yields from ketone 69 (Scheme 26). (S)-DHTP 
synthesis has been also described in a patent granted to Jiangnan University in 2019 [224]. The 
bioreduction of the starting ketone was carried out in the presence of different ketoreductases from 
different microorganisms, achieving the best results using a recombinant carbonyl reductase from 
Sche e 24. Synthesis of E 66 e ploying dehydrogenases.
A patent for the preparation of (1R,2S)-N-pyrrolidinyl norephedrine 68 by a bioreduction procedure
has been granted to Enzymeworks in 2019 [215]. This chiral compound is a valuable synthon
for the preparation of anti-AIDS drug efavirenz (Sustiva®) [216,217]. The starting ketone 67 was
selectively reduced in dynamic kinetic resolution catalysed by a KRED purchased from Suzhou Chinese
Biotechnology of Enzymes Co. (EW104), as indicated in Scheme 25. Isopropanol or glucose/GDH were
employed for the cofactor recycling. After reaction parameters optimization, enantiopure (1R,2S)-68
was recovered in high yields and with excellent purity.
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Scheme 25. Preparation of (1R,2S)-N-pyrrolidinyl norephedrine employing ketoreductases.
A patent granted to Goodee Pharma Co. Ltd. in 2016 described the preparation of different
3-piperidinols by employing two KREDs, which sequence is given, as biocatalysts [218]. The enzymes
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were employed in solution or as lyophilized powders or immobilized as free enzymes or as whole
cells, being employed glucose/GDH as secondary enzymatic system for the cofactor regeneration.
The application of a set of KREDs for the enantioselective reduction of different thienyl ketones to
the corresponding (S)-thienyl alcohols with excellent optical purities (>99% ee) and high conversions
has been patented in 2018 [219]. Alcohols thus obtained are valuable chiral synthons for the preparation
of duloxetine [220–222], the active enantiomer of this third generation antidepressant trademarked
as Cymbalta®. A patent granted in 2015 to Codexis Inc. afforded the bioreduction of a family of
3-aryl-3-ketopropanamines to (S)-3-aryl-3-hydroxypropanamines employing different engineered
KREDs, whose sequences are given [223]. Depending on the substrate structures, high conversions
were obtained after 24 h employing glucose/GDH for the NAD(P)+ recycling. The preparation of
(S)-N,N-dimethyl-3-hydroxy-3-(2-thienyl)-1-propanamine ((S)-DHTP, 70), a precursor in the synthesis
of duloxetine, was carried out with high yields from ketone 69 (Scheme 26). (S)-DHTP synthesis
has been also described in a patent granted to Jiangnan University in 2019 [224]. The bioreduction
of the starting ketone was carried out in the presence of different ketoreductases from different
microorganisms, achieving the best results using a recombinant carbonyl reductase from Candida
macedoniensis AKU 4588. Control of the reaction conditions allows obtaining (S)-DHTP in 92% yield
and 99% ee.
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organic cosolvents. NADP+ was recycled in presence of glucose/GDH and a fluorinated reagent was 
added at the end of the bioreduction in order to extract the product from the reaction media. Thus, 
HFE-7600 and/or F-626 were used for this purpose, being able to recover quantitatively the final 
alcohol with 98.2% ee. The preparation of other halogenated alcohols has been granted by Codexis 
Inc. in 2015 [231]. Thus, the patent described the preparation of chiral α-chloroalcohols from α-
Scheme 26. Synthesis of duloxetine employing chemoenzymatic methodologies with ketoreductases.
(R)-2-Hydroxy-4-phenylbutyric acid ethyl ester is a valuable intermediate in the preparation of
drugs employed to treat hypertension [225]. Its synthesis with a global yield of 82% starting from
benzaldehyde and pyruvic acid has been patented by Suzhou Lead Biotechnology Company Ltd. [226].
The final step of this procedure comprises the bioreduction of 2-oxo-4-phenylbutyric acid ethyl ester
in presence of glucose/GDH for the NADP+ recycling. After 20 h at 30 ◦C a 97% of the enantiopure
β-hydroxyester was recovered in this process. Similarly, in 2019, Genentech Inc. was granted a
patent [227] for the synthesis of (S)-1-(1-(4-chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-
pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (74), an ERK inhibitor and a useful medicament
for treating hyperproliferative disorders [228]. One of the steps for the preparation of this compound,
depicted in Scheme 27, comprises the bioreduction of 1-(4-chloro-3-fluorophenyl)-2-hydroxyethanone
(72) to (S)-1-(4-chloro-3-fluorophenyl)ethane-1,2-diol (S)-73 catalyzed by KRED-NADH-112
(Codexis Inc.) using glucose/GDH for the NAD+ recycling. The chiral alcohol was recovered
with quantitative conversion and 99.5% ee.
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Finally, fluoride-containing chiral alcohols are valuable compounds with a huge range of
applications in medicine, pesticides or liquid crystals [229]. A patent granted to Enzymeworks
in 2019 described the preparation of (S)-1,1,1-trifluoroisopropanol from trifluoroacetone employing
different KREDs [230]. Phosphate buffer pH 7.0 was used as reaction medium containing different
amounts of organic cosolvents. NADP+ was recycled in presence of glucose/GDH and a fluorinated
reagent was added at the end of the bioreduction in order to extract the product from the reaction
media. Thus, HFE-7600 and/or F-626 were used for this purpose, being able to recover quantitatively
the final alcohol with 98.2% ee. The preparation of other halogenated alcohols has been granted by
Codexis Inc. in 2015 [231]. Thus, the patent described the preparation of chiral α-chloroalcohols from
α-chloroketones as well as the polynucleotides encoding the engineered ketoreductases and the host
cells capable of expressing the engineered ketoreductases.
3.2. Imine Reductions
In the last few years, imine reductases (IREDs) have appeared as valuable biocatalysts for the
preparation of chiral amines by catalyzing the reduction of imines [232–240]. These enzymes are
involved in many natural processes such as the biosynthesis of cofactors, alkaloids and cyclic amino
acids. IREDs are enzymes requiring NAD(P)H, being this cofactor responsible of the imine reduction.
In 2017 and 2018, two patents granted to Codexis Inc. showed different engineered enzymes with
activity as imine reductases and applied these biocatalysts in the conversion of ketones and amines to
the corresponding optically active secondary and tertiary amines, as for instance the conversion of
cyclohexanone and L-norvaline to (S)-2-(cyclohexylamino)pentanoic acid [241,242]. On the other hand,
a patent granted in 2016 to Pfizer Inc. [243] described the use of IRED in combination with an amine
oxidase or a transaminase in one of the steps of the synthesis of pregabalin (discussed in Section 2.2,
see also Scheme 34 in Section 4).
3.3. Oxidations
Oxidation processes involving different types of biocatalysts as mild oxidants under mild
reaction conditions are employed are widely used nowadays while obtaining in general high
selectivities [244–254]. For this reason, processes in which oxidative enzymes are employed have been
patented in the last times. Most of the examples described the use of monooxygenases in different
oxidations; these enzymes are able to perform the insertion of one atom of oxygen in the substrate
from molecular oxygen, requiring nicotinamides as cofactors [255–259].
Esomeprazole (S)-76 (Scheme 28), is a proton pump inhibitor prescribed for the treatment of
dyspepsia, peptic ulcer disease and gastroesophageal reflux disease [260]. This compound is the
(S)-enantiomer of omeprazole, which is the racemic mixture of the (S) and (R) enantiomers. Thus, in a
patent granted in 2016 [261] a set of engineered cyclohexanone monooxygenases (CHMOs) from
Acinetobacter calcoaceticus [262] were employed in the asymmetric sulfoxidation of a set of prazoles,
including 5-methoxy-2-((4-methoxy-3,5-dimethylpyridin-2-yl)methylthio)-1H-benzodimidazole (75)
(Scheme 28a).
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The oxidation of these compounds in presence of recombinant CHMOs afforded the 
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oxidation of these compounds in prese ce of r combinant CHMOs afforded the corresponding
(R)- or (S)-sulfoxides 76 with excellent optical purities at mild temperatures. In o der to e su e a
c mplete conversion, dissolved molecu ar oxygen in the process can be increased y bubbling the
reactio with oxygen-containin gas r by use of bubble-fre aeration with oxygen-containing gas.
Different organic cosolvents were tested in the processes (MeOH, EtOH, IPA, acetonitrile, etc.) to
increase the substrate solubility. In order to regenerate the NAD(P)H employed as cofactor, secondary
enzymatic systems including glucose/GDH, glucose-6-phosphate/glucose-6-phosphate dehydrogenase
(G6PDH), formate/formate dehydrogenase (FDH), phosphite/phosphite dehydrogenase (PTDH) or
alcohol/ADH were used.
Engineered CHMOs have been also employed in the preparation of armodafinil ((R)-78,
Scheme 28b) and analogues, as shown in a patent granted in 2017 to Codexis [263]. Armodafinil
(Nuvigil®) is the active (R)-enantiomer of the racemic drug modafinil (Provigil®), employed
for the treatment of narcolepsy and other medical conditions [264,265]. The sulfoxidation
reaction was performed on both the amide substrate 2-(benzhydrylsulfinyl)acetamide 77 to obtain
armodafinil, 2-(R)-(diphenylmethyl)sulfinylacetamide (R)-78, or on the corresponding acid substrate,
benzhydryl-thioacetic acid to yield (R)-2-(benzhydrylsulfinyl)acetic acid, known as (R)-modafinil
(or modafinilic acid), which can be subsequently converted to the amide product in an easy way.
For both processes, high optical purities were obtained (>90% ee) under the optimized conditions
when carrying out the oxidations in phosphate buffer in presence of different cosolvents.
The use of cytochrome P450 [255,256,259] has been also described in patents for the preparation
of valuable compounds. Thus, in a patent granted in 2019 [266], different P450s obtained from Bacillus
subtilis and Bacillus cereus expressed in E. coli, in combination with an electron-transfer protein having
the activity to transfer an electron to the cytochrome P450, have been used as biocatalysts on the
oxidation of the 3-methylene position of α-guaiene 79 to lead (-)-rotundone 80, a molecule with several
applications in the fragrance industry [267], as shown in Scheme 29.
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peroxygenase activity [268]. Peroxygenases are biocatalysts capable of catalyse a very important 
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carbonyl acceptor. Of the two types of PLP-dependent TAs classified according to the type of 
substrate they convert [269], the use of α-TAs, exclusively converting α-amino and α-keto acids, is 
more limited, while ω-TAs can accept substrates with a distal carboxylate group. More specifically, 
amine TAs (ATAs), a subgroup of ω-TAs, are capable of accepting substrates not possessing a 
carboxylate group in their structures, have received substantial attention in recent years, because of 
their capability in the synthesis of chiral primary amines starting from the corresponding prochiral 
ketones [7,120,270]. 
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In 2015, Novozymes AS was granted a patent describing different fungal enzymes with
peroxygenase activity [268]. Peroxygenases are biocatalysts capable of catalyse a very important process
in organic chemistry such as the functionalisation of C–H bonds through the hydroxylation of both
non-activated and aromatic C–H bonds [252,254]. The patent included the activity and compositions of
these enzymes, their encoding polynucleotides, expression vectors and recombinant host cells as well
as the methods of producing the enzymes. Finally, these biocatalysts were applied in the regioselective
oxygenation of a set of N-heterocycles.
4. Granted Patents Related to Transaminases in Asymmetric Synthesis
Transaminases (TAs, type I and IV of pyridoxal 5′-phosphate (PLP)-dependent enzymes) are
enzymes capable of catalysing the reversible transfer of an amino group from a suitable donor to a
carbonyl acceptor. Of the two types of PLP-dependent TAs classified according to the type of substrate
they convert [269], the use of α-TAs, exclusively converting α-amino and α-keto acids, is more limited,
while ω-TAs can accept substrates with a distal carboxylate group. More specifically, amine TAs
(ATAs), a subgroup ofω-TAs, are capable of accepting substrates not possessing a carboxylate group
in their structures, have received substantial attention in recent years, because of their capability in the
synthesis of chiral primary amines starting from the corresponding prochiral ketones [7,120,270].
Consequently, transaminase sequences have been protected in several granted documents.
For instance, Hoffmann-La Roche and the Bornscheuer group have jointly patented (granted in 2018)
several mutants of the transaminase from Ruegeria sp., which are useful for transamination synthetic
reactions [271]. Likewise, Codexis has been active in identifying and protecting several transaminase
sequences, with several patents granted between 2015–2019, with special emphasis on the production of
(R)-ethyl-3-amino-3-(pyridine-2-yl)-propanoate derivatives [272–274]. An analogous sequence-based
approach for IP construction has been successfully applied by DSM (patent granted in 2017 [275]) and
Asymchem Laboratories (patent granted in 2019 [276]) with application of the novel transaminases
to particularly impeded ketones as substrates (e.g., m,m-Cl-disubstituted phenyl-, or naphthyl
acetophenones). Other examples describe the synthesis of L-aminobutyric acid, an intermediate
in the synthesis of anti-epileptic levetiracetam (see also Scheme 1) in a patent granted in 2018 [277],
as well as many other diverse synthetic purposes [278–280]. In the same field, the protection of novel
transaminase sequences has been combined with immobilization [281–283], to be used, for instance,
in the synthesis of antidiabetic sitagliptin (Januvia®, a dipeptidyl peptidase-4 (DPP-4) inhibitor which
was the first marketed oral antihyperglycemic drug belonging to the gliptin family [284]) through
transamination [285–287], following the pioneering example described by Merck and Codexis [288].
With respect to asymmetric synthesis, there are several remarkable examples of granted patents
using transaminases for the preparation of optically active amines, very relevant building blocks for
pharmaceutical chemistry as already mentioned before in Section 2.1.3 [117,118,120]. Herein, Lonza and
the Bornscheuer group have jointly focused on the synthesis of N-amino-pyrrolidines and piperidines,
using transaminases with alanine as amino donor in two patents granted between 2014 and
2017 [289,290]; thus, the formed by-product pyruvate (from alanine) can be decarboxylated by means of
a pyruvate decarboxylase (PDC), or reduced by using a dehydrogenase, to shift the equilibrium towards
the product formation. In another example granted in 2017 [291], transaminases have been used for the
synthesis of different 3-amino-pyrrolydines 82 and 86, starting from the correspondent functionalized
Catalysts 2019, 9, 802 22 of 42
oxopyrrolidines 81 and 84, using isopropyl-amine as amino donor (Scheme 30). The products formed
undergo subsequent cyclization, and provide access to pyrrolo[3,4-b]pyridine structures 83 and 86,
precursors of pharmaceuticals, e.g., the broad-spectrum antibiotic moxifloxacin (Avelox®, Vigamox®
or Moxiflox®, amongst others) [292]. Remarkably, when the protecting group (PG) is an ester, the use
of lipases (namely CALB) for the deprotection step is considered in the invention as well.
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Likewise, Codexis has described a patented process, granted in 2015 [293] for the synthesis of 
(1R,2R)-2-(3,4-dimethoxyphenethoxy)-cyclohexanamine (R,R)-88, starting from the correspondent 
enantiopure ketone (R)-87 by using specific sequences of transaminases, as depicted in Scheme 31. 
The obtained amine is an intermediate in the synthesis of vernakalant, an ion channel blocker useful 
Scheme 30. Use of transaminases to afford 3-aminopyrrolidines, as precursors of pharmaceutical
compounds, e.g., moxifloxacin.
Likewise, Codexis has described a patented process, granted in 2015 [293] for the synthesis of
(1R,2R)-2-(3,4-dimethoxyphenethoxy)-cyclohexanamine (R,R)-88, starting from the correspondent
enantiopure ketone (R)-87 by using specific sequences of transaminases, as depicted in Scheme 31.
The obtained amine is an intermediate in the synthesis of vernakalant, an ion channel blocker useful
for the treatment of atrial fibrillation [294,295]. As amino donor, isopropyl-amine was used, and DMSO
was added as co-solvent. Substrate loadings of >10 g/L have been claimed for the invention.
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in 2018 [303] protects the synthesis of (R,R)-90, a precursor of efinaconazole (Jublia®, Clenafin®),
an anti-fungal drug [304,305], using transaminase variants able to accept the sterically hindered
substrate (R)-89 (Scheme 32).
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Another relevant example is the transaminase-catalyzed synthesis of L-glufosinate, which is a
broad-spectrum herbicide [306], starting from the correspondent oxoacid 91 (Scheme 33). The specific
sequence of the transaminase is provided as well in the patent granted in 2018 [307].
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In the same field, the company Agrimetis LLC has patented a two-step enzymatic method for the
synthesis of L-glufosinate, starting either from D-glufosinate or from the corresponding racemic mixture.
In the first step, a D-amino acid oxidase forms the correspondent keto-acid, which is subsequently
aminated by a transaminase in the second step [308]. The sequences of both enzymes are protected as
well, and the immobilization of them is considered too.
Another active field is the synthesis of pregabalin (Lyrica®), a medication used for anxiety disorder,
epilepsy, neurophatic pains, fibromyalgia, restless leg syndrome, etc. [169,170], already discussed in
previous sections. In fact, Pfizer has patented a route ([243], granted in 2017), that covers all the synthetic
steps for the generation of the amine precursor 92, which is then subjected to a transaminase-catalyzed
reaction to introduce the chirality and produce pregabalin, as depicted in Scheme 34. The use of an
amine oxidase or an imine reductase is considered and protected as well.
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In an analogous area, Merck has patented a transaminase route ([309], granted in 2018) involving
dynamic kinetic resolution for the synthesis of optically active amines, useful as precursors of drugs
such as the anti-cancer agent niraparib [109].
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As already shown in several examples (see above), the use of multi-step enzymatic processes is a
rather common approach, as the properties of several biocatalysts can be combined for performing
efficient asymmetric syntheses. Thus, MH2 Biochemical Ltd has patented a process for the synthesis
of D-alanine, using racemases and amino transferases, being expressed as a fusion enzyme in a
whole-cell [310]. In an analogous fashion, the use of lipases and transaminases are combined to deliver
optically active β-amino acids, as well as precursors for the sitagliptin synthesis [311]. A further
approach in this respect is the use of transaminases with opposite enantioselectivity for deracemization
purposes, starting from racemic amino acids, as shown in Scheme 35 [312,313]. As depicted, the racemic
(R,S)-93 is used as amino donor by a D-amino acid transaminase, rendering the desired amino acid
(R)-95 from the keto acid 94. The subsequent byproduct, the keto acid 96, is recycled back to the
racemic mixture by means of an (S)-transaminase, which uses isopropylamine as sacrificial amino
donor. Overall, it represents an outstanding example on how the exquisite selectivity of enzymes may
be smartly used for synthetic purposes.Catalysts 2019, 9, x FOR PEER REVIEW 24 of 41 
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focus on improved activities, and including thermostability as well. Likewise, BASF (Verenium) has 
protected ([317], granted in 2015) the use of ammonia lyases, covering PAL and TAL variants, and 
broadening their invention to histidine ammonia lyases as well. With a focus on other enzyme types, 
in a patent granted in 2015 [318], Firmenich has covered the sequence of a 13-hydroperoxide lyase 
(with an alteration of more than 40 amino acids compared to the wild-type sequence). The novel 
variant is employed in a reaction involving several polyunsaturated fatty acids (e.g. alpha-linolenic), 
to yield 3-(Z)-hexen-ol. Other examples are related to novel sequences of hydroxynitrile lyases, such 
as a patent granted 2018 of the Asano research group [319], or another one granted in 2015 from 
Evocatal [320]. Similarly, in a patent granted in 2014, DSM has protected hydroxynitrile lyases that 
can catalyze the asymmetric synthesis of sterically hindered cyanohydrins (e.g. starting from ortho-
benzaldehyde derivatives as substrates) [321]. 
With respect to applications in asymmetric synthesis, tyrosine phenol lyases have found 
applications in the field of cathecol- and phenyl- amine derivatives. For instance, Changxing 
Pharmaceutical Ltd company has developed in a patent granted in 2018 [322] a process for the 
synthesis of L-DOPA, which is used as an anti-Parkinsonian drug [323–325]. In a similar area, the 
Rother group has protected in two patents granted 2018 and 2017 [326,327] the synthesis of the 
psychoactive drug cathine ((1S,2S)-nor-pseudoephedrine) [328,329], through a multi-step enzymatic 
reaction combining the use of Acetobacter pasteurianus pyruvate decarboxylase as (S)-selective lyase 
(C-C forming type [330,331]), together with the transaminase of Chromobacterium violaceum as (S)-
selective transaminase, as depicted in Scheme 36.  
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5. Granted Patents Related to Lyases in Asymmetric Synthesis
Apart from other enzymes (see previous sections), lyases (EC 4.1.X.X, enzymes catalysing bond
forming and breaking through non-hydrolytic or redox mechanisms) have also been matter of IP
activity over the last five years, with relevant examples in the pharmaceutical and fine chemicals
fields. As a common strategic working line for IP construction, several industries have focused on
the (successful) protection of novel sequences of lyases (establishing several degrees of homology),
which can be subsequently used for biocatalytic purposes. As relevant examples, Codexis was granted
patents ([314], granted in 2019) that comprise examples of phenylammonia lyase variants (PAL, a C-N
lyase [315]) with improved tolerance to pH, higher activity, or resistance to enzymatic proteolysis
(key amino acidic residues of the sequence are given). In a similar approach, another patent granted in
2019 [316] protect novel another C-N lyase, tyrosine ammonia lyase variants (TAL), with analogous
focus on improved activities, and including thermostability as well. Likewise, BASF (Verenium) has
protected ([317], granted in 2015) the use of ammonia lyases, covering PAL and TAL variants, and
broadening their invention to histidine ammonia lyases as well. With a focus on other enzyme types,
in a patent granted in 2015 [318], Firmenich has covered the sequence of a 13-hydroperoxide lyase
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(with an alteration of more than 40 amino acids compared to the wild-type sequence). The novel variant
is employed in a reaction involving several polyunsaturated fatty acids (e.g., alpha-linolenic), to yield
3-(Z)-hexen-ol. Other examples are related to novel sequences of hydroxynitrile lyases, such as a patent
granted 2018 of the Asano research group [319], or another one granted in 2015 from Evocatal [320].
Similarly, in a patent granted in 2014, DSM has protected hydroxynitrile lyases that can catalyze the
asymmetric synthesis of sterically hindered cyanohydrins (e.g., starting from ortho-benzaldehyde
derivatives as substrates) [321].
With respect to applications in asymmetric synthesis, tyrosine phenol lyases have found
applications in the field of cathecol- and phenyl- amine derivatives. For instance, Changxing
Pharmaceutical Ltd company has developed in a patent granted in 2018 [322] a process for the synthesis
of L-DOPA, which is used as an anti-Parkinsonian drug [323–325]. In a similar area, the Rother group has
protected in two patents granted 2018 and 2017 [326,327] the synthesis of the psychoactive drug cathine
((1S,2S)-nor-pseudoephedrine) [328,329], through a multi-step enzymatic reaction combining the use
of Acetobacter pasteurianus pyruvate decarboxylase as (S)-selective lyase (C-C forming type [330,331]),
together with the transaminase of Chromobacterium violaceum as (S)-selective transaminase, as depicted
in Scheme 36.
Catalysts 2019, 9, x FOR PEER REVIEW 25 of 41 
 
 
Scheme 36. Process for the synthesis of cathine, combining several enzymes and starting from 
inexpensive substrates. 
As starting substrates, benzaldehyde and either acetaldehyde or pyruvic acid could be 
successfully employed. This has enabled the (re)use of pyruvic acid generated as by-product during 
the transaminase reaction when using L-alanine as amino donor, leading to a fully integrated multi-
step enzymatic process with high selectivity and productivity to the desired compound [332,333]. 
The technology has been recently extended to other substrates (e.g. 2, 5-dimethoxybenzaldehyde) to 
afford other synthetically relevant building blocks [334]. 
Another relevant field of innovation with lyases (involving granted patents) is the synthesis of 
statins, from which many biocatalytic applications have been envisioned and comprehensively 
reviewed elsewhere [110], and some patents granted involving statins synthesis have been already 
commented on in Sections 2.1.3 and 3.1. Hence, several industries have been working on the use of 
lyases for this process, with different focuses to successfully build the IP. For instance, Lek 
Pharmaceuticals holds several patents granted in 2017 and 2018 [335–337], in which the innovation is 
based on the use of novel substrates, e.g. the use of 2,2-dimethoxyethanal to react with two 
equivalents of acetaldehyde, as well as on the use of aldolases (DERA) with novel sequences, and 
further enzymatic oxidation to the lactol derivative. An analogous strategy has been used by Pfizer, 
protecting novel DERA sequences to be used as catalysts for the reaction of N-protected substrates 
such as 99 and 100. Specifically, the introduction of 3-phtalimidopropionaldehyde 97 and 3-
succinimido-propionaldehyde 98 as substrates (Scheme 37) has been successfully protected in a 
patent granted in 2014 [338]. 
 
Scheme 37. Pfizer approach, using several N-substituted substrates, for the synthesis of statins. 
In a similar approach, Mitsui Chemicals has based its innovation patented in 2016 on the 
protection of a DERA with a specific sequence [339], whereas QR Pharmaceuticals Ltd has patented 
the use of carbamates as N-protected substrates, to afford the synthesis of the statin side-chain using 
lyases ([340], granted in 2017). 
Scheme 36. Process for the synthesis of cathine, combining several enzymes and starting from
inexpensive substrates.
As starting substrates, benzaldehyde and either acetaldehyde or pyruvic acid could be successfully
employed. This has enabled the (re)use of pyruvic acid generated as by-product during the transaminase
reaction when using L-alanine as amino donor, leading to a fully integrated multi-step enzymatic
process with high selectivity and productivity to the desired compound [332,333]. The technology
has been recently extended to other substrates (e.g., 2, 5-dimethoxybenzaldehyde) to afford other
synthetically relevant building blocks [334].
Another relevant field of innovation with lyases (involving granted patents) is the synthesis of
statins, from which many biocatalytic applications have been envisioned and comprehensively reviewed
elsewhere [110], and some patents granted involving statins synthesis have been already commented
on in Sections 2.1.3 and 3.1. Hence, several industries have been working on the use of lyases for this
process, with different focuses to successfully build the IP. For instance, Lek Pharmaceuticals holds
several patents granted in 2017 and 2018 [335–337], in which the innovation is based on the use of novel
substrates, e.g., the use of 2,2-dimethoxyethanal to react with two equivalents of acetaldehyde, as well
as on the use of aldolases (DERA) with novel sequences, and further enzymatic oxidation to the lactol
derivative. An analogous strategy has been used by Pfizer, protecting novel DERA sequences to be used
as catalysts for the reaction of N-protected substrates such as 99 and 100. Specifically, the introduction
of 3-phtalimidopropionaldehyde 97 and 3-succinimido-propionaldehyde 98 as substrates (Scheme 37)
has been successfully protected in a patent granted in 2014 [338].
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In a similar approach, Mitsui Chemicals has based its innovation patented in 2016 on the protection
of a DERA with a specific sequence [339], whereas QR Pharmaceuticals Ltd has patented the use of
carbamates as N-protected substrates, to afford the synthesis of the statin side-chain using lyases ([340],
granted in 2017).
Other examples of granted patents involving lyases are the synthesis of tagatose using novel
variant sequences of fructose biphosphate aldolases [341,342], granted 2016 and 2015), or the synthesis
of L-aminobutyric acid starting from glycine and ethanol as readily available substrates, and using a
multi-sept process comprising an alcohol dehydrogenase, a threonine aldolase, a threonine deaminase,
and a L-amino acid dehydrogenase ([343], granted 2018). Likewise, the Kroutil group has patented
a process granted in 2016 [344,345] and presented in Scheme 38, in which p-vinyl- phenols 104 are
produced along a three-step, one-pot reaction starting with substituted phenols 101, pyruvic acid and
ammonia as substrates. Thus, the action of a tyrosine-phenol-lyase (TPL) leads to the formation of
L-tyrosine derivatives (S)-102. Remarkably, chirality generated upon furnishing the corresponding
aminoacids is afterwards destroyed along the course of the process. Subsequently, phenyl-ammonia
lyase (PAL or TAL) renders the substituted p-coumaric acids 103, which are finally decarboxylated by a
phenolic-acid decarboxylase (PAD) to afford the desired p-vinylphenols 104 in high yields.
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6. Summary and Outlook
Biocatalysis is an interdisciplinary field, in which the interaction of scientists with different
backgrounds is necessary, namely, biology, chemistry, engineering, business, etc. On this basis, it offers
many opportunities for innovation, and for the construction of novel IP structures. To reflect that
innovation, a survey on patentability actions related to biocatalysis and asymmetric synthesis is given
within this paper. To reinforce their innovative step, only granted patents have been considered.
The result is a vast area of enzyme uses, covering all types, and performed by industry and academic
groups. Several key ideas for innovation have been found. One is the protection of novel protein
sequences for well-known reactions. Another one is the use of novel substrates for useful synthetic
reactions. Further innovative lines (ending in granted patents) are the combination of different enzymes,
as well as the set-up of other technical reaction parameters for improved processes. Based on the
obtained results, it can be concluded that biocatalysis is taking significant steps in chemical industries,
being seriously considered as a powerful alternative for combining sustainable chemistry with high
efficiency and selectivity.
Author Contributions: All authors (P.D.d.M., G.d.G. and A.R.A.) equally contributed to this manuscript.
Funding: This research received no external funding.
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